A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

• Huvudupphovsmän: Mariane Teodoro Fernandes (Författare, medförfattare), Jacob J Adashek (Författare, medförfattare), Carmelia Maria Noia Barreto (Författare, medförfattare), Ana Cláudia Barbin Spinosa (Författare, medförfattare), Barbara de Souza Gutierres (Författare, medförfattare), Gilberto Lopes (Författare, medförfattare), Auro del Giglio (Författare, medförfattare), Pedro Nazareth Aguiar Jr (Författare, medförfattare)
• Materialtyp: Bok
• Publicerad: BioExcel Publishing Ltd, 2018-11-01T00:00:00Z.
• Ämnen: article
• Länkar: Connect to this object online.

Sammanfattning

In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. All of the approved drugs exhibit progression-free survival benefit when compared to standard of care and generally have less adverse events compared to traditional chemotherapeutic options. The treatment of HR+/HER2- advanced breast cancer is a continuously evolving landscape, and the addition of CDK4/6 inhibitors is the newest mechanism for treatment. In this review, we summarize all available data, highlight the unanswered questions, and discuss pharmacological differences between each CDK4/6 inhibitor.

Beskrivning

10.7573/dic.212555
1740-4398
1740-4398